Refine by
T Cell Receptor Based Cell Therapy Suppliers & Manufacturers
26 companies found
based inHolytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
based inCarlsbad, CALIFORNIA (USA)
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering ...
TILs are part of the body’s natural response to cancer:The cells of the immune system perform immunosurveillance while circulating throughout the bodyAs part of the normal immune response, TIL migrate to the tumor site through recognition of ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
based inSchlieren, SWITZERLAND
We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. ...
based inMarlborough, MASSACHUSETTS (USA)
Cytiva, now with the life sciences business from Pall, is a global provider of technologies, services, and expertise to help researchers and companies protect and preserve the planet for improved human health and safety. Our products offer quality, ...
based inNew York, NEW YORK (USA)
IN8bio was founded in 2016 with the mission of developing novel therapies to address cancer. The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product ...
INB-200, our DeltEx DRI, is a genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors. This is the first genetically engineered gamma-delta T cell therapy to be administered to patients and our initial ...
based inBerlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
based inMawson Lakes, AUSTRALIA
Carina Biotech is an Australian pre-clinical immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. CAR-T therapy is a revolutionary new treatment option that uses a ...
based inSherman Oaks, CALIFORNIA (USA)
T-Cure is a clinical-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to bringing new targets and therapies to the T-Cell Receptor (TCR) field that have a high ...
T cell engineering with TCRs is a growing area of immuno-oncology with recent breakthroughs in clinical settings. The T-Cure approach involves identifying and isolating a high avidity TCR which specifically recognizes an intracellular or ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
based inDuisburg, GERMANY
Genekam Biotechnology AG was found in 1999. It started offering DNA-Tests in 2001. From 2004, it started development of PCR kits while exporting to 5 countries, today (2015) it exports to 70 countries in the world. Genekam covers different targets ...
There are many laboratories developing CAR T-cell therapies. Genekam has a number of kits to develop CAR T-Cell therapy e.g. isolate large number of T cells (CD4 / CD8) from blood or other source. This isolation kit will generate larger number of ...
based inMilano, ITALY
We are a clinical-stage biotechnology company pioneering the treatment of cancers with a technology platform that allows the direct delivery of immunotherapeutic payloads within the tumor microenvironment. Intrinsic resistance significantly reduces ...
based inSouth San Francisco, CALIFORNIA (USA)
We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen-fighting immune cells and is uniquely capable of enhancing ...
based inPhiladelphia, PENNSYLVANIA (USA)
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T ...
based inBerkeley, CALIFORNIA (USA)
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell ...
CAR-T cell therapies are a class of treatments in which T cells are modified to express chimeric antigen receptors (CARs). CARs are engineered molecules that, when present on the surface of a T cell, enable a T cell to recognize a specific protein ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
based inMont-Saint-Guibert, BELGIUM
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. We are developing a diversified pipeline of allogeneic and autologous CAR T cell ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
The chimeric T cell antigen receptor therapy, also known as CAR-T, is an immunotherapy that is innovating the treatment of hematological and solid tumors. This new technology is considered less aggressive than conventional treatments, since it ...
based inCarlton South, AUSTRALIA
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease ...
Cell therapy is the transfer of intact, live cells into a patient to help lessen or cure a disease. The most common and simple type of cell therapy is a blood transfusion. Other commonly known cell therapies include red and white blood cell ...